Cymbalta, Tykerb, Tysabri on U.S. drug safety list
WASHINGTON, Sept 5 (Reuters) - U.S. health officials said on Friday they are probing safety concerns with Eli Lilly and Co's (LLY.N: Quote, Profile, Research, Stock Buzz) antidepressant Cymbalta, GlaxoSmithKline's (GSK.L: Quote, Profile, Research, Stock Buzz) cancer drug Tykerb, Biogen Idec (BIIB.O: Quote, Profile, Research, Stock Buzz) and Elan Corp's (ELN.I: Quote, Profile, Research, Stock Buzz) multiple sclerosis drug Tysabri and other medicines.
The drugs were included among 20 products on a new quarterly list of medicines undergoing early safety probes following reports from the public of health problems.
Appearing on the list does not mean the Food and Drug Administration has concluded that the drug caused the problem, the agency said.
The FDA is evaluating reports of urinary retention with Cymbalta, liver toxicity with Tykerb and skin melanoma with Tysabri, according to the list which can be found at: here (Reporting by Susan Heavey and Lisa Richwine; editing by Tim Dobbyn)
© Thomson Reuters 2008 All rights reserved
Ads by Career Builder
Revenue Cycle Management/ Healthcare
Details: Growing Healthcare Consultancy organization...seeks experienced Healthcare Revenue Cycle Management...initiatives to healthcare providers and payers...
Work from Home as a Healthcare Recruiter
Details: ...from Home as a Healthcare Recruiter Health...an international healthcare recruiting and...represents high-demand healthcare professionals and...
Regional Operations Director - Healthcare
Details: ...Operations Director - Healthcare This position will...skills/experience: Healthcare Multi-Site Management...benefits including the healthcare industry's most...
Lawson Analyst - Payroll for healthcare
Details: ...experience within a healthcare industry environment...Application Analyst, Healthcare Systems, Payroll...Analyst - Payroll for healthcare position, and have...
Space beer lands in Japan
